<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03081689</url>
  </required_header>
  <id_info>
    <org_study_id>GECP 16/03_NADIM</org_study_id>
    <nct_id>NCT03081689</nct_id>
  </id_info>
  <brief_title>Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients</brief_title>
  <official_title>Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Lung Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Lung Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and
      efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W
      + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult
      patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months
      and Nivolumab 480mg Q4W for 8 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and
      efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W
      + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult
      patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months
      and Nivolumab 480mg Q4W for 8 months.

      Three cycles of neoadjuvant chemotherapy in combination with nivolumab will be administered.

      After completion of neoadjuvant therapy (3 cycles) and before surgery, a tumor assessment
      will be done. Patients are allowed to leave the study if there is evidence of progression.
      These patients may be considered for surgery.

      Report imaging response vs pathological response rate will be evaluated.

      Patients eligible for the trial are those with a histological diagnosis or cytologically
      proven operable and resectable non-small-cell lung cancer. The total number of patients to be
      included will be 46 from 23 participating sites in Spain.

      Accrual period of 1.5 years or until the inclusion of the last patient necessary to achieve
      the sample set in the protocol of 46 patients. After that all patients will be treated for 1
      year with adjuvant immunotherapy and they will be followed during 3 years after adjuvant
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>at 24 months from the first dose of neadjuvant treatment</time_frame>
    <description>The progression free survival is the time until the patients disease progresses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 3 years from the first dose of neoadjuvant treatment</time_frame>
    <description>Time when the patient is still alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>from the first dose of neoadjuvant treatment until 90 days after the last dose of adjuvant treatment</time_frame>
    <description>Toxicities caused by the drug during the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab 360 mg</intervention_name>
    <description>Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel 200mg/m2</intervention_name>
    <description>Paclitaxel 200mg/m2 IV Q3W</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin AUC 6</intervention_name>
    <description>Carboplatin AUC 6 IV Q3W</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Carboplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subjects eligible for the study are those with histologically- or cytologically-
             documented NSCLC who present stage IIIA disease

          2. Tumor should be considered resectable before study entry

          3. Performance Status of 0 or 1

          4. Screening laboratory values must meet the following criteria and should be obtained
             within 14 days prior to registration/inclusion i. WBC ≥ 2000/μL ii. Neutrophils ≥
             1500/μL iii. Platelets ≥ 100 x103/μL iv. Hemoglobin &gt; 9.0 g/dL v. Serum creatinine ≤
             1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault
             formula below): a. Female CrCl = (140 - age in years) x weight in kg x 0.85

        1. 72 x serum creatinine in mg/dL

        b. Male CrCl = (140 - age in years) x weight in kg x 1.00

          1. 72 x serum creatinine in mg/dL vi. AST/ALT ≤ 3 x ULN vii. Total Bilirubin ≤ 1.5 x ULN
             (except subjects with Gilbert Syndrome, who can have total bilirubin &lt; 3.0 mg/dL)
             viii. The patients need to have a forced expiratory volume (FEV1) ≥ 1.2 liters ix.
             INR/APTT within normal limits

             5. All patients are notified of the investigational nature of this study and signed a
             written informed consent

             6. Patients aged &gt; 18 years

             7. Women of childbearing potential (WOCBP) must use appropriate method(s) of
             contraception.

             8. Women must not be breastfeeding

             9. Men who are sexually active with WOCBP must use any contraceptive method with a
             failure rate of less than 1% per year.

             Exclusion Criteria:

               1. All patients carrying activating mutations in the TK domain of EGFR or any
                  variety of alterations in the ALK gene.

               2. Patients with active, known or suspected autoimmune disease.

               3. Patients with a condition requiring systemic treatment with either
                  corticosteroids (&gt;10 mg daily prednisone equivalent) or other immunosuppressive
                  medications within 14 days of randomization.

               4. Patients with a history of interstitial lung disease cannot be included if they
                  have sympthomatic ILD (Grade 3-4)

               5. Patients with other active malignancy requiring concurrent intervention

               6. Patients with previous malignancies (except non-melanoma skin cancers, and the
                  following in situ cancers: bladder, gastric, colon, endometrial,
                  cervical/dysplasia, melanoma, or breast) are excluded unless a

               7. Any medical, mental or psychological condition which in the opinion of the
                  investigator would not permit the patient to complete the study

               8. Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2,
                  anti-CTLA-4 antibody,

               9. Patients with positive test for hepatitis B virus surface antigen (HBV sAg) or
                  hepatitis C virus ribonucleic acid (HCV antibody)

              10. Patients with known history of testing positive for human immunodeficiency virus
                  (HIV)

              11. Patients with history of allergy to study drug components excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariano Provencio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>spanish Lun Cancer Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Pereira</last_name>
    <phone>93 430 20 06</phone>
    <email>epereira@gecp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Fernández</last_name>
    <phone>93 430 20 06</phone>
    <email>secretaria@gecp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo hospitalario de la coruña</name>
      <address>
        <city>La Coruña</city>
        <state>Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosario García Campelo, MD-phD</last_name>
    </contact>
    <investigator>
      <last_name>Rosario García Campelo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Cordoba</city>
        <state>Córdoba</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isidoro Barneto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isidoro Barneto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Insular de Gran Canaria</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Gran Canaria</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delvys Rodríguez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Delvys Rodríguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano Provencio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mariano Provencio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ignacio Gil-Bazo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ignacio Gil-Bazo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36212</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Casal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joaquin Casal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo López Vicanco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillermo López Vicanco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartomeu Massutí, MD-phD</last_name>
    </contact>
    <investigator>
      <last_name>Bartomeu Massutí</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Quirón Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Santiago Viteri, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Santiago Viteri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Álex Martínez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Álex Martínez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nuria Viñolas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nuria Viñolas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Majem, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Margarita Majem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Duran i Reynals-ICO</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ernest Nadal, MD</last_name>
      <phone>+34932607332</phone>
    </contact>
    <investigator>
      <last_name>Ernest Nadal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Miguel Sánchez, MD</last_name>
      <phone>+34915202479</phone>
    </contact>
    <investigator>
      <last_name>José Miguel Sánchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Luis González Larriba, MD</last_name>
    </contact>
    <investigator>
      <last_name>José Luis González Larriba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Dómine, MD</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Dómine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier de Castro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier de castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mónica Guillot, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mónica Guillot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elvira del Barco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elvira del Barco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de La Macrena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Vicente, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Vicente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reyes Bernabé, MD</last_name>
    </contact>
    <investigator>
      <last_name>Reyes Bernabé</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Insa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Insa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Gen. Univ. Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Camps, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carlos Camps, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Codina</last_name>
    </contact>
    <investigator>
      <last_name>José Codina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gecp.org</url>
    <description>Web page of the sponsor where users can find more information about SLCG studies</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

